{"product_id":"flow-cytometry-of-hematological-malignancies-isbn-9781119611257","title":"Flow Cytometry of Hematological Malignancies","description":"Flow Cytometry of Hematological Malignancies \u003cp\u003eFlow cytometric analysis is often integral to the swift and accurate diagnosis of leukemias and lymphomas of the blood, bone marrow, and lymph nodes. However, in the fast-moving and expanding field of clinical hematology, in can be challenging to remain up to speed with the latest biological research and technological innovations. \u003ci\u003eFlow Cytometry of Hematological Malignancies\u003c\/i\u003e has been designed to provide all those working in hematological oncology with a practical, cutting-edge handbook, featuring clear and fully illustrated guidance on all aspects of cytometry’s role in diagnosis and analysis. This essential second edition includes:\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eExplorations of more than 70 antigens\u003c\/li\u003e\n\u003cli\u003eFull-color illustrations throughout\u003c\/li\u003e\n\u003cli\u003eNew descriptions of recently discovered markers\u003c\/li\u003e\n\u003cli\u003eWHO classifications of hematological neoplastic diseases\u003c\/li\u003e\n\u003cli\u003eHelpful tips for result interpretation and analysis\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003eFeaturing all this and more, \u003ci\u003eFlow Cytometry of Hematological Malignancies, Second Edition,\u003c\/i\u003e is an invaluable resource for both trainee and experienced hematologists, hematopathologists, oncologists, and pathologists, as well as medical students and diagnostic lab technicians.Flow Cytometry of Hematological Malignancies bietet eine Vielzahl grafisch aufbereiteter Ergebnisse, die mit der Durchflusszytometrie bei der Untersuchung der häufigsten Erkrankungen gewonnen wurden. Auch weniger bekannte Krankheiten werden vorgestellt.\u003cbr\u003e \u003cbr\u003e Das Fachbuch wurde als Referenzwerk zum schnellen Nachschlagen konzipiert. Es ist ein Muss für Kliniker, die hämatologische Erkrankungen diagnostizieren und analysieren, darunter Hämatologen, Hämatopathologen, Onkologen, Pathologen und Mitarbeiter in diagnostischen Labors.\u003cbr\u003e \u003c\/p\u003e\u003cp\u003eForeword to the Second Edition xi\u003cbr\u003e\u003ci\u003eby Michael J. Borowitz\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eForeword to the First Edition xii\u003cbr\u003e\u003ci\u003eby Maryalice Stetler-Stevenson\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eForeword to the First Edition xiii\u003cbr\u003e\u003ci\u003eby Bruno Brando\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003ePreface to the Second Edition xv\u003c\/p\u003e \u003cp\u003ePreface to the First Edition xvi\u003c\/p\u003e \u003cp\u003eAbbreviations xvii\u003c\/p\u003e \u003cp\u003e\u003cb\u003e1 Antigens 1\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eClustered (CD) Antigens\u003c\/p\u003e \u003cp\u003eCD1 3\u003c\/p\u003e \u003cp\u003eCD2 5\u003c\/p\u003e \u003cp\u003eCD3 8\u003c\/p\u003e \u003cp\u003eCD4 17\u003c\/p\u003e \u003cp\u003eCD5 21\u003c\/p\u003e \u003cp\u003eCD7 24\u003c\/p\u003e \u003cp\u003eCD8 26\u003c\/p\u003e \u003cp\u003eCD10 30\u003c\/p\u003e \u003cp\u003eCD11b 35\u003c\/p\u003e \u003cp\u003eCD11c 38\u003c\/p\u003e \u003cp\u003eCD13 40\u003c\/p\u003e \u003cp\u003eCD14 44\u003c\/p\u003e \u003cp\u003eCD15 46\u003c\/p\u003e \u003cp\u003eCD16 49\u003c\/p\u003e \u003cp\u003eCD19 52\u003c\/p\u003e \u003cp\u003eCD20 55\u003c\/p\u003e \u003cp\u003eCD22 59\u003c\/p\u003e \u003cp\u003eCD23 61\u003c\/p\u003e \u003cp\u003eCD24 64\u003c\/p\u003e \u003cp\u003eCD25 66\u003c\/p\u003e \u003cp\u003eCD26 67\u003c\/p\u003e \u003cp\u003eCD27 69\u003c\/p\u003e \u003cp\u003eCD28 70\u003c\/p\u003e \u003cp\u003eCD30 71\u003c\/p\u003e \u003cp\u003eCD33 73\u003c\/p\u003e \u003cp\u003eCD34 77\u003c\/p\u003e \u003cp\u003eCD38 79\u003c\/p\u003e \u003cp\u003eCD43 81\u003c\/p\u003e \u003cp\u003eCD45 82\u003c\/p\u003e \u003cp\u003eCD45 Isoforms 87\u003c\/p\u003e \u003cp\u003eCD49 90\u003c\/p\u003e \u003cp\u003eCD56 93\u003c\/p\u003e \u003cp\u003eCD57 96\u003c\/p\u003e \u003cp\u003eCD61 97\u003c\/p\u003e \u003cp\u003eCD62L 98\u003c\/p\u003e \u003cp\u003eCD64 99\u003c\/p\u003e \u003cp\u003eCD65 101\u003c\/p\u003e \u003cp\u003eCD66c 102\u003c\/p\u003e \u003cp\u003eCD71 103\u003c\/p\u003e \u003cp\u003eCD79 104\u003c\/p\u003e \u003cp\u003eCD81 107\u003c\/p\u003e \u003cp\u003eCD103 108\u003c\/p\u003e \u003cp\u003eCD117 110\u003c\/p\u003e \u003cp\u003eCD123 112\u003c\/p\u003e \u003cp\u003eCD138 113\u003c\/p\u003e \u003cp\u003eCD200 114\u003c\/p\u003e \u003cp\u003eCD305 116\u003c\/p\u003e \u003cp\u003eCD307 (IRTA) Antigen Family 117\u003c\/p\u003e \u003cp\u003eCD371 118\u003c\/p\u003e \u003cp\u003eNon clustered (or primarily known with other names) antigens Bcl‐2 Protein 119\u003c\/p\u003e \u003cp\u003eChemokines and Chemokine Receptors 121\u003c\/p\u003e \u003cp\u003eCRLF2 128\u003c\/p\u003e \u003cp\u003eCytotoxic Proteins 129\u003c\/p\u003e \u003cp\u003eHLA‐DR 130\u003c\/p\u003e \u003cp\u003eImmunoglobulins 132\u003c\/p\u003e \u003cp\u003eKIR, CD158 isoforms 136\u003c\/p\u003e \u003cp\u003eMyeloperoxidase (MPO) 139\u003c\/p\u003e \u003cp\u003eNG2 140\u003c\/p\u003e \u003cp\u003ePCA‐1 141\u003c\/p\u003e \u003cp\u003eROR1 141\u003c\/p\u003e \u003cp\u003eSLAM Molecules and SLAM‐associated Protein (SAP) 142\u003c\/p\u003e \u003cp\u003eSOX11 144\u003c\/p\u003e \u003cp\u003eT‐cell Receptor (TCR) 145\u003c\/p\u003e \u003cp\u003eTerminal Deoxy‐nucleotidyl‐transferase (TdT) 148\u003c\/p\u003e \u003cp\u003eToll‐like Receptors (TLR) 150\u003c\/p\u003e \u003cp\u003eVS38 151\u003c\/p\u003e \u003cp\u003eZAP‐70 152\u003c\/p\u003e \u003cp\u003e\u003cb\u003e2 Diseases 155\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eMyeloproliferative neoplasms 157\u003c\/p\u003e \u003cp\u003eChronic myeloid leukemia (CML) 157\u003c\/p\u003e \u003cp\u003eMyeloproliferative neoplasms other than CML 160\u003c\/p\u003e \u003cp\u003eChronic neutrophilic leukemia (CNL) 160\u003c\/p\u003e \u003cp\u003ePolycythemia vera (PV) 160\u003c\/p\u003e \u003cp\u003ePrimary myelofibrosis (PMF) 160\u003c\/p\u003e \u003cp\u003eEssential thrombocythemia (ET) 160\u003c\/p\u003e \u003cp\u003eChronic eosinophilic leukemia (CEL) 161\u003c\/p\u003e \u003cp\u003eMastocytosis 162\u003c\/p\u003e \u003cp\u003eAcute mast‐cell leukemia (AMCL) 162\u003c\/p\u003e \u003cp\u003eChronic mast‐cell leukemia (CMCL) 163\u003c\/p\u003e \u003cp\u003eMyelomastocytic leukemia (MML) 163\u003c\/p\u003e \u003cp\u003eMyelodysplastic\/myeloproliferative neoplasms 164\u003c\/p\u003e \u003cp\u003eChronic myelomonocytic leukemia (CMML) 164\u003c\/p\u003e \u003cp\u003eOther myelodysplastic\/myeloproliferative neoplasms and related conditions 167\u003c\/p\u003e \u003cp\u003eJuvenile myelomonocytic leukemia (JMML) 167\u003c\/p\u003e \u003cp\u003eAtypical CML bcr\/abl negative (ACML) 167\u003c\/p\u003e \u003cp\u003eRAS‐associated autoimmune leukoproliferative disorder (RALD) 167\u003c\/p\u003e \u003cp\u003eMyelodysplastic syndromes 168\u003c\/p\u003e \u003cp\u003eMyeloid neoplasms with germline predisposition 171\u003c\/p\u003e \u003cp\u003eAcute myeloid leukemias 172\u003c\/p\u003e \u003cp\u003eAMLs with recurrent genetic anomalies 173\u003c\/p\u003e \u003cp\u003eAMLs with chromosomal anomalies 173\u003c\/p\u003e \u003cp\u003eAMLs with gene mutations 180\u003c\/p\u003e \u003cp\u003eRelationships between genotype and phenotype in cases of AML not recognized as separate entities in WHO 2017 181\u003c\/p\u003e \u003cp\u003eAMLs with myelodysplasia‐related changes (AML‐MRC) 182\u003c\/p\u003e \u003cp\u003eAMLs not otherwise specified 182\u003c\/p\u003e \u003cp\u003eAML with minimal differentiation 182\u003c\/p\u003e \u003cp\u003eAML without maturation 183\u003c\/p\u003e \u003cp\u003eAML with maturation 183\u003c\/p\u003e \u003cp\u003eAcute myelomonocytic leukemia (AMMoL) 183\u003c\/p\u003e \u003cp\u003eAcute monoblastic and monocytic leukemia (AMoL) 184\u003c\/p\u003e \u003cp\u003ePure erythroid leukemia (PEL) 185\u003c\/p\u003e \u003cp\u003eAcute megakaryoblastic leukemia (AMKL) 186\u003c\/p\u003e \u003cp\u003eAcute basophilic leukemia (ABL) 188\u003c\/p\u003e \u003cp\u003eMyeloid proliferations associated with Down syndrome 188\u003c\/p\u003e \u003cp\u003eTransient abnormal myelopoiesis (TAM) 189\u003c\/p\u003e \u003cp\u003eAMLs in patients with Down syndrome 189\u003c\/p\u003e \u003cp\u003eBlastic plasmacytoid dendritic cell neoplasm (BPDCN\/PDCL) 189\u003c\/p\u003e \u003cp\u003eAcute leukemias with ambiguous lineage attribution (ALAL) 192\u003c\/p\u003e \u003cp\u003eAcute undifferentiated leukemias (AUL) 192\u003c\/p\u003e \u003cp\u003eMixed phenotype acute leukemias (MPAL) 192\u003c\/p\u003e \u003cp\u003eNeoplastic diseases of B and T lymphatic precursors 194\u003c\/p\u003e \u003cp\u003eB lymphoblastic leukemia\/lymphoma, not otherwise specified (B‐ALL\/LBLnos) 195\u003c\/p\u003e \u003cp\u003eB lymphoblastic leukemia\/lymphoma with recurrent genetic anomalies 197\u003c\/p\u003e \u003cp\u003eRelationships between genotype and phenotype in cases of B‐ALL not recognized as separate entities in WHO 2017 201\u003c\/p\u003e \u003cp\u003eT lymphoblastic leukemia\/lymphoma (T‐ALL\/LBL) 202\u003c\/p\u003e \u003cp\u003eEarly T‐cell precursor lymphoblastic leukemia (ETP‐ALL) 205\u003c\/p\u003e \u003cp\u003eNK lymphoblastic leukemia\/lymphoma (NK‐ALL\/LBL) 205\u003c\/p\u003e \u003cp\u003eNeoplastic diseases of mature B cells 206\u003c\/p\u003e \u003cp\u003eChronic lymphocytic leukemia\/small\u003c\/p\u003e \u003cp\u003elymphocytic lymphoma (B‐CLL\/SLL) 206\u003c\/p\u003e \u003cp\u003eFamilial B‐CLL 215\u003c\/p\u003e \u003cp\u003eRichter syndrome 215\u003c\/p\u003e \u003cp\u003eMonoclonal B‐cell lymphocytosis (MBL) 216\u003c\/p\u003e \u003cp\u003eCLL‐like monoclonal B lymphocytosis 216\u003c\/p\u003e \u003cp\u003eNon‐CLL‐like monoclonal B lymphocytosis 216\u003c\/p\u003e \u003cp\u003eB‐cell prolymphocytic leukemia (B‐PLL) 216\u003c\/p\u003e \u003cp\u003eLymphoplasmacytic lymphoma (LPL) 218\u003c\/p\u003e \u003cp\u003eHeavy chain disease (HCD) 221\u003c\/p\u003e \u003cp\u003eγ heavy chain disease 222\u003c\/p\u003e \u003cp\u003eμ heavy chain disease 222\u003c\/p\u003e \u003cp\u003eα heavy chain disease 222\u003c\/p\u003e \u003cp\u003eHairy cell leukemia (HCL) 222\u003c\/p\u003e \u003cp\u003eHairy cell leukemia, variant (HCL‐v) 226\u003c\/p\u003e \u003cp\u003eHairy cell leukemia, Japanese variant (HCL‐J) 227\u003c\/p\u003e \u003cp\u003eSplenic diffuse red pulp lymphoma (SDRPL) 227\u003c\/p\u003e \u003cp\u003eMarginal zone lymphomas (MZL) 228\u003c\/p\u003e \u003cp\u003eNodal marginal zone lymphoma (NMZL) 229\u003c\/p\u003e \u003cp\u003eSplenic marginal zone lymphoma (SMZL) 230\u003c\/p\u003e \u003cp\u003eExtranodal marginal zone lymphoma (EMZL\/MALToma) 232\u003c\/p\u003e \u003cp\u003eClonal B‐cell lymphocytosis with MZL‐like phenotype (CBL‐MZ) 233\u003c\/p\u003e \u003cp\u003eFollicular lymphoma (FCL) 234\u003c\/p\u003e \u003cp\u003eTesticular follicular lymphoma 237\u003c\/p\u003e \u003cp\u003eDuodenal type follicular lymphoma 237\u003c\/p\u003e \u003cp\u003ePediatric type follicular lymphoma 237\u003c\/p\u003e \u003cp\u003ePrimitive cutaneous follicular lymphoma (PCFL) 237\u003c\/p\u003e \u003cp\u003eLarge B‐cell lymphoma with IRF4 rearrangement 237\u003c\/p\u003e \u003cp\u003eMantle‐cell lymphoma (MCL) 237\u003c\/p\u003e \u003cp\u003eBlastic mantle‐cell lymphoma (BMCL) 240\u003c\/p\u003e \u003cp\u003eLeukemic non nodal mantle‐cell lymphoma 240\u003c\/p\u003e \u003cp\u003eDLBCL not otherwise specified (DLBCLnos) 240\u003c\/p\u003e \u003cp\u003eCD5(+) diffuse large cell lymphoma (CD5(+) DLBCL) 243\u003c\/p\u003e \u003cp\u003eT‐cell\/histiocyte‐rich B‐cell lymphoma (THRLBCL) 243\u003c\/p\u003e \u003cp\u003ePrimary DLBCL of the CNS (PCNSL) 244\u003c\/p\u003e \u003cp\u003ePrimary cutaneous DLBCL, “leg type” 244\u003c\/p\u003e \u003cp\u003eEBV(+) DLBCLnos 244\u003c\/p\u003e \u003cp\u003eDLBCL associated with chronic inflammation (PAL) 245\u003c\/p\u003e \u003cp\u003eFibrin associated DLBCL 245\u003c\/p\u003e \u003cp\u003eLymphomatoid granulomatosis (LYG) 245\u003c\/p\u003e \u003cp\u003ePrimary mediastinal B‐cell lymphoma (PMBCL) 245\u003c\/p\u003e \u003cp\u003eIntravascular large B‐cell lymphoma (IVBCL) 246\u003c\/p\u003e \u003cp\u003eALK‐positive large cell lymphoma (ALK(+) LBCL) 246\u003c\/p\u003e \u003cp\u003ePlasmablastic lymphoma (PBL) 247\u003c\/p\u003e \u003cp\u003ePrimary effusion lymphoma (PEL) 247\u003c\/p\u003e \u003cp\u003eHHV8‐associated lymphoproliferative disorders 247\u003c\/p\u003e \u003cp\u003eHHV8‐positive DLBCL 248\u003c\/p\u003e \u003cp\u003eHHV8‐positive germinotropic lymphoproliferative disorder 248\u003c\/p\u003e \u003cp\u003eBurkitt lymphoma (BL) 248\u003c\/p\u003e \u003cp\u003eBurkitt leukemia with immature phenotype 250\u003c\/p\u003e \u003cp\u003eBurkitt‐like lymphoma with 11q aberrations 251\u003c\/p\u003e \u003cp\u003eHigh‐grade B‐cell lymphoma (HGBL) 251\u003c\/p\u003e \u003cp\u003ePlasma cell neoplasms 251\u003c\/p\u003e \u003cp\u003eMonoclonal gammopathies of undetermined significance (MGUS) 253\u003c\/p\u003e \u003cp\u003eMultiple myeloma (MM) 253\u003c\/p\u003e \u003cp\u003ePlasma cell leukemia (PCL) 257\u003c\/p\u003e \u003cp\u003eNeoplastic diseases of mature T and NK cells 258\u003c\/p\u003e \u003cp\u003eT‐cell prolymphocytic leukemia (T‐PLL) 258\u003c\/p\u003e \u003cp\u003eT‐cell large granular lymphocytic leukemia (T‐LGL) 261\u003c\/p\u003e \u003cp\u003eChronic lymphoproliferative disorders of NK cells (CLPD‐NK\/CNKL) 263\u003c\/p\u003e \u003cp\u003eAggressive NK‐cell leukemia (ANKL) 266\u003c\/p\u003e \u003cp\u003eAdult T‐cell leukemia\/lymphoma (ATLL) 266\u003c\/p\u003e \u003cp\u003eExtranodal NK\/T-cell lymphoma, “nasal type” (ENKTL) 269\u003c\/p\u003e \u003cp\u003eIntestinal T‐cell lymphomas (ITCL) 270\u003c\/p\u003e \u003cp\u003eEnteropathy‐associated T‐cell lymphoma (EATCL) 270\u003c\/p\u003e \u003cp\u003eMonomorphic epitheliotropic intestinal T‐cell lymphoma (MEITL) 272\u003c\/p\u003e \u003cp\u003eIndolent gastro‐intestinal T lymphoproliferative disorder (indolent GI T‐LPD) 273\u003c\/p\u003e \u003cp\u003eHepatosplenic T‐cell lymphoma (HSTCL) 273\u003c\/p\u003e \u003cp\u003eSubcutaneous panniculitis‐like T‐cell lymphoma (SPTCL) 275\u003c\/p\u003e \u003cp\u003eMycosis fungoides (MF) 275\u003c\/p\u003e \u003cp\u003eSezary syndrome (SS) 277\u003c\/p\u003e \u003cp\u003ePrimary cutaneous CD30(+) lymphoproliferative disorders 279\u003c\/p\u003e \u003cp\u003eLymphomatoid papulosis (LyP) 279\u003c\/p\u003e \u003cp\u003ePrimary cutaneous anaplastic T‐cell lymphoma (pcALCL) 279\u003c\/p\u003e \u003cp\u003ePrimary cutaneous peripheral T‐cell lymphoma (PTCL) 280\u003c\/p\u003e \u003cp\u003ePrimary cutaneous TCRγδ(+) T‐cell lymphoma (PCGD‐TCL) 280\u003c\/p\u003e \u003cp\u003ePrimary cutaneous CD8(+) aggressive epidermotropic cytotoxic T‐cell lymphoma (PCAETL) 280\u003c\/p\u003e \u003cp\u003ePrimary cutaneous acral CD8(+) T‐cell lymphoma (PCATCL) 280\u003c\/p\u003e \u003cp\u003ePrimary cutaneous lymphoma of the medium\/small CD4(+) T cells (PCSM‐TCL) 281\u003c\/p\u003e \u003cp\u003ePeripheral T‐cell lymphoma, not otherwise specified (PTCLnos) 281\u003c\/p\u003e \u003cp\u003eNodal lymphomas of follicular T‐helper derivation 283\u003c\/p\u003e \u003cp\u003eAngioimmunoblastic T‐cell lymphoma (AITL) 283\u003c\/p\u003e \u003cp\u003eFollicular T‐cell lymphoma (FTCL) 285\u003c\/p\u003e \u003cp\u003eNodal PTCL with follicular T‐helper phenotype 285\u003c\/p\u003e \u003cp\u003eAnaplastic large cell lymphoma ALK(+) (ALCL ALK(+)) 285\u003c\/p\u003e \u003cp\u003eAnaplastic large cell lymphoma ALK(‐) (ALCL ALK(‐)) 288\u003c\/p\u003e \u003cp\u003eBreast implant–associated anaplastic large cell lymphoma (biaALCL) 288\u003c\/p\u003e \u003cp\u003eHodgkin lymphomas 289\u003c\/p\u003e \u003cp\u003eClassic Hodgkin lymphoma (CHL) 289\u003c\/p\u003e \u003cp\u003eNodular lymphocyte predominant Hodgkin lymphoma (NLPHL) 290\u003c\/p\u003e \u003cp\u003eNeoplastic diseases of histiocytic and dendritic cells 291\u003c\/p\u003e \u003cp\u003eHistiocytic sarcoma (HS) 292\u003c\/p\u003e \u003cp\u003eLangerhans cell histiocytosis (LCH) 292\u003c\/p\u003e \u003cp\u003eIndeterminate dendritic cell tumor (IDCT) 292\u003c\/p\u003e \u003cp\u003eInterdigitating dendritic cell sarcoma (IDCS) 292\u003c\/p\u003e \u003cp\u003eFollicular dendritic cell sarcoma (FDCS) 292\u003c\/p\u003e \u003cp\u003eErdheim–Chester disease (EDC) 292\u003c\/p\u003e \u003cp\u003e\u003cb\u003e3 Appendix 293\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eAcute leukemias not recognized by the 2017 WHO classification 294\u003c\/p\u003e \u003cp\u003eAcute leukemia of myeloid\/NK precursors (M\/NK‐AL) 294\u003c\/p\u003e \u003cp\u003eAcute leukemia of myeloid dendritic cells (MDCL) 294\u003c\/p\u003e \u003cp\u003eAcute leukemia of Langerhans cells 294\u003c\/p\u003e \u003cp\u003eComposite lymphomas 294\u003c\/p\u003e \u003cp\u003eHypereosinophilic syndrome (HES), lymphocyte variant 295\u003c\/p\u003e \u003cp\u003eIndolent T lymphoblastic proliferations (iT‐LBP) 295\u003c\/p\u003e \u003cp\u003ePolyclonal lymphocytoses of B lymphocytes 298\u003c\/p\u003e \u003cp\u003ePersistent polyclonal B‐cell lymphocytosis (PPBL) 298\u003c\/p\u003e \u003cp\u003ePersistent polyclonal CD5(+) B‐cell lymphocytosis 298\u003c\/p\u003e \u003cp\u003ePersistent polyclonal B‐cell lymphocytosis, Japanese (hairy) variant 298\u003c\/p\u003e \u003cp\u003ePolyclonal plasmacytoses 299\u003c\/p\u003e \u003cp\u003eSmall round (blue) cell tumors (SR(B)CT) 300\u003c\/p\u003e \u003cp\u003eReferences 301\u003c\/p\u003e \u003cp\u003eIndex 429\u003c\/p\u003e \u003cp\u003e\u003cb\u003eAbout the author\u003c\/b\u003e\u003c\/p\u003e\u003cp\u003e\u003cb\u003eClaudio Ortolani\u003c\/b\u003e is an expert in the area of diagnosis of hematological malig­­nancies. Now retired, Dr Ortolani was Consultant in the Department of Clinical Pathology at Venice General Hospital, Venice, Italy. He is one of the founding members of the Italian Society for Cytometric Cell Analysis (ISCCA), of whose board he is currently a member. He has taught and lectured internationally on how to use flow cytometry to aid in diagnosing hematological diseases.\u003c\/p\u003e  \u003cp\u003eFlow cytometric analysis is often integral to the swift and accurate diagnosis of leukemias and lymphomas of the blood, bone marrow, and lymph nodes. However, in the fast-moving and expanding field of clinical hematology, in can be challenging to remain up to speed with the latest biological research and technological innovations. \u003ci\u003eFlow Cytometry of Hematological Malignancies\u003c\/i\u003e has been designed to provide all those working in hematological oncology with a practical, cutting-edge handbook, featuring clear and fully illustrated guidance on all aspects of cytometry’s role in diagnosis and analysis. This essential second edition includes:\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eExplorations of more than 70 antigens\u003c\/li\u003e\n\u003cli\u003eFull-color illustrations throughout\u003c\/li\u003e\n\u003cli\u003eNew descriptions of recently discovered markers\u003c\/li\u003e\n\u003cli\u003eWHO classifications of hematological neoplastic diseases\u003c\/li\u003e\n\u003cli\u003eHelpful tips for result interpretation and analysis\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003eFeaturing all this and more, \u003ci\u003eFlow Cytometry of Hematological Malignancies, Second Edition,\u003c\/i\u003e is an invaluable resource for both trainee and experienced hematologists, hematopathologists, oncologists, and pathologists, as well as medical students and diagnostic lab technicians.\u003c\/p\u003e","brand":"Wiley-Blackwell","offers":[{"title":"Default Title","offer_id":47989222670565,"sku":"NP9781119611257","price":204.95,"currency_code":"USD","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1842\/7735\/files\/9781119611257.jpg?v=1761783266","url":"https:\/\/k12savings.com\/products\/flow-cytometry-of-hematological-malignancies-isbn-9781119611257","provider":"K12savings","version":"1.0","type":"link"}